Medtronic has completed its acquisition of Scientia Vascular, a privately held medical device company based in Salt Lake City, in a deal worth USD 550 million, subject to customary adjustments and potential additional milestone and earn-out payments.
The acquisition strengthens Medtronic’s neurovascular portfolio by adding Scientia’s advanced access technologies, including guidewires and catheters.
Linnea Burman, senior vice president and president of Medtronic’s Neurovascular business within the Neuroscience Portfolio, said the addition of Scientia’s access technologies strengthens their ability to simplify complex neurovascular procedures and support physicians with more seamless solutions.
“By bringing together highly complementary technologies, we are building a more integrated platform that will help advance the future of neurovascular care and enable physicians to treat more patients with greater efficiency and confidence,” Burman added.
Scientia CEO Rick Randall said Medtronic’s global reach would help expand access to Scientia’s technology worldwide.
Stroke remains one of the leading causes of death and disability globally, and timely treatment is critical, as millions of brain cells can be lost within a second of interrupted blood flow.
Cerebral blood vessels are highly complex and tortuous, creating significant challenges for physicians attempting to reach the site of an occlusion or aneurysm. Difficult access can delay therapy delivery and impact procedural success.
Scientia’s novel access platform has been designed to address these challenges by improving navigability through complex anatomy during neurovascular procedures, enabling faster and more reliable access while enhancing procedural efficiency.
Medtronic expects the deal to have a minimal dilutive impact on adjusted earnings per share in FY27 before becoming accretive in subsequent years.
